Two pre-TURBT 40-mg intravesical mitomycin-C instillations significantly improved long-term recurrence outcomes versus TURBT ...
Detalimogene voraplasmid achieved a 54.0% any-time CR in BCG-unresponsive NMIBC with CIS ± high-grade Ta/T1, with 91% of CRs ...
CAR T therapy spreads beyond academic centers, but insurance, cost and policy gaps keep most eligible lymphoma patients from ...
VIKTORIA-2 Trial Evolves to Evaluate Gedatolisib in Endocrine-Sensitive and -Resistant Breast Cancer
Significant protocol amendments have been made to the ongoing phase 3 VIKTORIA-2 clinical trial (NCT06757634).The study, ...
FDA fast track status was supported by two monotherapy responses in MSI-H colorectal cancer, including one complete response ...
A new program for young cancer patients breaks disease silos, showing how multidisciplinary teamwork improves coordination, ...
Dr. Doroshow addresses financial toxicity as a central concern in Sandra's case and broader challenge in HER2-directed ...
Complete response at 3 months was 79.6% (191/240), with duration-of-response estimates showing a gradual attrition over time ...
Dr. Leal addresses diagnostic challenges with newer therapies, particularly tarlatamab's potential neurologic side effects ...
Andrzej Jakubowiak, MD, PhD, director of the multiple myeloma program at the University of Chicago, discusses the definitive results of the phase 3 ATLAS trial (NCT02659293), recently published in The ...
Allogeneic hematopoietic cell transplantation (alloHCT) using tremtelectogene empogeditemcel (trem-cel), a CRISPR–Cas9–edited ...
During a live event, Binod Dhakal, MD, discussed the evidence for targeting XPO1 and GPRC5D before BCMA CAR T-cell therapy in multiple myeloma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results